Stock AnalizAlignment Healthcare, Inc. ALHC
Medical Specialities · IPO 2021 · data as of November 13, 2026
Alignment Healthcare, Inc. (ALHC) is a healthcare company listed in the US with a market value of about $1.5B. In the twelve months to September 30, 2026 it had revenue of $4.9B and net income of $29M, a net margin of 0.6%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (4/5); the weakest is track record (1/5).
Key numbers: a P/E of 56.6, a price to free cash flow of 20.0, 5-year revenue growth of 33% a year, a 5-year average ROIC of -24%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 8% above the current price.
Score: 2.0 / 5
Checks passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
- ROE above 15%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.9B | $3.9B | $2.7B | $1.8B | $1.4B | $1.2B | $959M | $757M |
| Net income | $29M | -$724000 | -$128M | -$148M | -$150M | -$195M | -$23M | -$45M |
| Free cash flow | $77M | $113M | -$7M | -$95M | -$69M | — | — | — |
| EPS (diluted) | $0.13 | $0.00 | $-0.67 | $-0.79 | $-0.83 | $-1.14 | $-0.15 | $-0.33 |
| Net margin | 0.6% | -0.0% | -4.7% | -8.1% | -10.4% | -16.7% | -2.4% | -5.9% |
| ROIC | — | 2.3% | -18.6% | -38.8% | -25.0% | -38.1% | -2.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 12 analysts is $10.79, 47% above the current price; targets range from $8.00 to $17.00; the consensus rating is “Buy”; expected EPS is $0.27 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Alignment Healthcare’s P/E ratio?
About 56.6, based on the last twelve months of diluted earnings per share (forward P/E about 29.0).
Is Alignment Healthcare stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 8% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Alignment Healthcare pay a dividend?
Not currently.
Is Alignment Healthcare a good stock to buy?
We do not give buy or sell advice. Alignment Healthcare scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.